View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
November 2, 2011

Alios BioPharma and Versitech partner for influenza therapy

Alios BioPharma has signed an exclusive worldwide licensing agreement with Versitech to develop, manufacture and market medication to combat influenza viruses.

Alios BioPharma has signed an exclusive worldwide licensing agreement with Versitech to develop, manufacture and market medication to combat influenza viruses.

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

In addition, the companies have also entered into two other influenza-related, non-exclusive licence agreements and a sponsored research agreement.

Alios will sponsor collaborative research at the University of Hong Kong, as Versitech is its technology transfer company.

Alios BioPharma president and CEO Lawrence Blatt said that the compounds and technology derived from the deal will provide key therapeutic options to help improve patients infected from influenza virus.

Related Companies

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena